C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight

(Albany, USA) DelveInsight's, "C-Met Mutated Non-Small Cell Lung Cancer Pipeline Insight 2025" constitutes 5+ key companies continuously working towards developing 5+ C-Met Mutated Non-Small Cell Lung Cancer treatment therapies, analyzes DelveInsight.

The C-Met Mutated Non-Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

C-Met Mutated Non-Small Cell Lung Cancer Overview:
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) is characterized by an overexpression of the C-Met tyrosine kinase receptor, which is typically found in epithelial cells. Activation of C-Met leads to the phosphorylation of specific tyrosine residues (Y1003, Y1313, Y1230/1234/1235, Y1349, and Y1365), triggering multiple downstream signaling pathways such as RAS/ERK, PI3K/AKT, and cSRC kinase pathways. Due to SRC activation, C-Met is recognized as a key driver of epithelial-mesenchymal transition, promoting high levels of hepatocyte growth factor (HGF) and intratumoral C-Met expression-factors that are closely linked to NSCLC biology and prognosis. NSCLC is classified into three main types based on cellular morphology: squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Major risk factors for NSCLC include smoking, radiation exposure, and contact with hazardous substances such as asbestos, arsenic, and chromium.

Request for a detailed insights report on C-Met Mutated Non-Small Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/report-store/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

"C-Met Mutated Non-Small Cell Lung Cancer Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the C-Met Mutated Non-Small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Report
• DelveInsight's C-Met Mutated Non-Small Cell Lung Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for C-Met Mutated Non-Small Cell Lung Cancer treatment.
• Key C-Met Mutated Non-Small Cell Lung Cancer companies such as Novartis, Apollomics Inc., Abbvie, Janssen Research and Development, and others are evaluating new drugs for C-Met Mutated Non-Small Cell Lung Cancer to improve the treatment landscape.
• Promising C-Met Mutated Non-Small Cell Lung Cancer pipeline therapies in various stages of development include EGF-816 (Nazartinib), APL 101 (Bozitinib), and others.

Recent breakthroughs in the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Segment:
• In January 2025:- AbbVie:- A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
• June 2024:- AbbVie- A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
• May 2024: Apollomics Inc.- Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors.
• In May 2020, Novartis received FDA approval for Tabrecta, an oral MET inhibitor specifically targeting metastatic NSCLC with mutations leading to MET exon 14 skipping (METex14). This approval marked the first therapy designed for this particular genetic mutation. Clinical trials demonstrated an overall response rate of 68% in treatment-naïve patients and 41% in previously treated patients.

C-Met Mutated Non-Small Cell Lung Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the C-Met Mutated Non-Small Cell Lung Cancer Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for C-Met Mutated Non-Small Cell Lung Cancer treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the C-Met Mutated Non-Small Cell Lung Cancer market.

Download our free sample page report on C-Met Mutated Non-Small Cell Lung Cancer pipeline insights @ https://www.delveinsight.com/sample-request/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

C-Met Mutated Non-Small Cell Lung Cancer Emerging Drugs
• EGF-816 (Nazartinib): Novartis Oncology
• APL 101 (Bozitinib): Appolomics Inc.

C-Met Mutated Non-Small Cell Lung Cancer Companies
There are over five key companies actively developing therapies for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC). Among them, companies such as Novartis Oncology and others have drug candidates currently in mid-to-advanced stages of development, including Phase III clinical trials.

DelveInsight's report covers around 5+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

C-Met Mutated Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

C-Met Mutated Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging C-Met Mutated Non-Small Cell Lung Cancer Therapies and Key Companies: C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

C-Met Mutated Non-Small Cell Lung Cancer Pipeline Therapeutic Assessment
• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Product Type
• C-Met Mutated Non-Small Cell Lung Cancer By Stage
• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Route of Administration
• C-Met Mutated Non-Small Cell Lung Cancer Assessment by Molecule Type

Download C-Met Mutated Non-Small Cell Lung Cancer Sample report to know in detail about the C-Met Mutated Non-Small Cell Lung Cancer treatment market @ C-Met Mutated Non-Small Cell Lung Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Report Introduction
2. Executive Summary
3. C-Met Mutated Non-Small Cell Lung Cancer Current Treatment Patterns
4. C-Met Mutated Non-Small Cell Lung Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. C-Met Mutated Non-Small Cell Lung Cancer Late-Stage Products (Phase-III)
7. C-Met Mutated Non-Small Cell Lung Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. C-Met Mutated Non-Small Cell Lung Cancer Discontinued Products
13. C-Met Mutated Non-Small Cell Lung Cancer Product Profiles
14. C-Met Mutated Non-Small Cell Lung Cancer Key Companies
15. C-Met Mutated Non-Small Cell Lung Cancer Key Products
16. Dormant and Discontinued Products
17. C-Met Mutated Non-Small Cell Lung Cancer Unmet Needs
18. C-Met Mutated Non-Small Cell Lung Cancer Future Perspectives
19. C-Met Mutated Non-Small Cell Lung Cancer Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/c-met-mutated-non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.